6-K 1 q32026financialstatements.htm 6-K Document

  
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of October 2026
Commission File Number: 001-40488
 
MOLECULAR PARTNERS AG
(Exact name of registrant as specified in its charter)
 
Wagistrasse 14
8952 Zürich-Schlieren
Switzerland
Telephone: +41 447557700
(Address of registrant’s principal executive offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒  Form 20-F    ☐  Form 40-F





EXPLANATORY NOTE

Molecular Partners AG (the "Registrant") is filing this Form 6-K to furnish (i) a press release the Registrant issued on
October 29, 2026, (ii) condensed consolidated interim financial statements (unaudited) as of, and for the three and nine months ended, September 30, 2026 (including accompanying notes thereto), which are furnished herewith as Exhibit 99.1 and 99.2, respectively.
Exhibits 99.1 and 99.2 to this Report on Form 6-K, excluding any financial guidance, quotes of management, website addresses or hyperlinks included therein, shall be deemed to be incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File No. 333-286488) and Forms S-8 (File No. 333-272974 and File No. 333-280491, 333-288313 and 333-296995) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.




Condensed consolidated interim financial statements (unaudited)

Condensed consolidated interim statement of financial position as of
September 30, 2026
December 31, 2025
in CHF thousands
Note
Assets
Property, plant and equipment
3,786 
5,229 
Intangible assets
— 
2 
Total non-current assets
3,786 
5,231 
Short-term time deposits
— 
10,405 
Other current assets
1,667 
1,985 
Trade and other receivables
1,569 
1,834 
Cash and cash equivalents
57,493 
82,653 
Total current assets
60,729 
96,876 
Total assets
64,515 
102,107 
Shareholders' equity and liabilities
Share capital
5.2 
4,037 
4,037 
Additional paid-in capital
391,937 
389,179 
Treasury share reserve
5.2 
(1,240)
(1,129)
Cumulative losses
(344,072)
(311,753)
Total shareholders' equity
50,662 
80,334 
Trade and other payables160 160 
Lease liability
1,528 
2,438 
Employee benefits
2,757 
8,147 
Total non-current liabilities
4,445 
10,746 
Trade and other payables
1,205 
1,767 
Accrued expenses
6,991 
8,055 
Lease liability
1,212 
1,206 
Total current liabilities
9,408 
11,027 
Total liabilities
13,853 
21,772 
Total shareholders' equity and liabilities
64,515 
102,107 
See accompanying notes, which form an integral part of these unaudited condensed consolidated interim financial statements.


Condensed consolidated interim statement of profit or loss and other comprehensive result for the 9 months ended September 30,
2026
2025
in CHF thousands
Note
Revenues and other income
Revenues from research and development collaborations
5.1 
— 
— 
Total revenues and other income
— 
— 
Operating expenses
Research and development expenses
(27,331)
(30,954)
Selling, general and administrative expenses
(11,762)
(11,815)
Restructuring expenses
5.10
— (2,733)
Total operating expenses
(39,093)
(45,502)
Operating result
(39,093)
(45,502)
Financial income
5.5 
713 
1,288 
Financial expenses
5.5 
(30)
(4,790)
Net finance result
683 
(3,502)
Result before income taxes
(38,410)
(49,004)
Income taxes
5.6 
— 
2 
Net result, attributable to shareholders
(38,410)
(49,002)
Other comprehensive result
Items that will not be reclassified to profit or loss
Remeasurement of net pension liabilities, net of tax
5.8 
6,078 
(301)
Items that are or may be reclassified subsequently to profit or loss
Exchange differences on translating foreign operations
13 
9 
Other comprehensive result, net of tax
6,091 
(292)
Total comprehensive result, attributable to shareholders
(32,319)
(49,295)
Basic and diluted net result per share (in CHF)
5.7 
(1.01)
(1.32)
    
See accompanying notes, which form an integral part of these unaudited condensed consolidated interim financial statements.


Condensed consolidated interim statement of profit or loss and other comprehensive result for the 3 months ended September 30,
2026
2025
in CHF thousands
Note
Revenues and other income
Revenues from research and development collaborations
5.1
— 
— 
Total revenues and other income
— 
— 
Operating expenses
Research and development expenses
(8,276)
(8,328)
Selling, general and administrative expenses
(3,785)
(3,602)
Restructuring expenses
5.10
— (116)
Total operating expenses
(12,061)
(12,045)
Operating result
(12,061)
(12,045)
Financial income
5.5 
362 
366 
Financial expenses
5.5 
(9)
(157)
Net finance result
353 
209 
Result before income taxes
(11,708)
(11,836)
Income taxes
5.6
— 
— 
Net result, attributable to shareholders
(11,708)
(11,836)
Other comprehensive result
Items that will not be reclassified to profit or loss
Remeasurement of net pension liabilities, net of tax
5.8 
2,808 
(372)
Items that are or may be reclassified subsequently to profit or loss
Exchange differences on translating foreign operations
4 
3 
Other comprehensive result, net of tax
2,812 
(370)
Total comprehensive result, attributable to shareholders
(8,896)
(12,206)
Basic and diluted net result per share (in CHF)
5.7 
(0.31)
(0.33)
See accompanying notes, which form an integral part of these unaudited condensed consolidated interim financial statements.


Condensed consolidated interim cash flow statement for the 9 months ended September 30,
2026
2025
in CHF thousands
Net result attributable to shareholders
(38,410)
(49,002)
Adjustments for:
Depreciation and amortization
1,464 
1,632 
Share-based compensation
2,784 
3,446 
Social security and tax paid on behalf of employees on shares vested under the PSU and RSU program
(406)
(322)
Other equity-settled transactions
169 — 
Change in employee benefits
687 
(770)
Income tax
— 
(2)
Financial income
(713)
(1,288)
Financial expenses
30 
4,790 
Changes in working capital:
Change in other current assets
247 
131 
Change in trade and other receivables
276 
215 
Change in trade and other payables
(568)
425 
Change in accrued expenses
(1,064)
687 
Exchange gain/(loss) on working capital positions
(7)
(24)
Interest paid on lease liabilities
(18)
(12)
Other financial expense
(12)
(11)
Net cash used in operating activities
(35,541)
(40,106)
Proceeds from investments in short term time deposits
18,257 
115,591 
Investments in short term time deposits
(8,036)
(55,765)
Acquisition of property, plant and equipment
(20)
(575)
Interest received
301 
1,346 
Net cash from investing activities
10,501 
60,597 
Proceeds from issuance of shares under LTI plans— 1 
Proceeds from vesting under the LTI plans
100 
62 
Payment of lease liabilities
(903)
(912)
Net cash used in financing activities
(803)
(849)
Exchange gain (loss) on cash positions
683 
(1,159)
Net increase (decrease) in cash and cash equivalents
(25,160)
18,485 
Cash and cash equivalents at January 1
82,653 
63,874 
Cash and cash equivalents at September 30,
57,493 
82,359 
See accompanying notes, which form an integral part of these unaudited condensed consolidated interim financial statements.


Condensed consolidated interim statement of changes in equity
in CHF thousands
Share capital
Additional paid-in capital
Treasury share reserve
Cumulative losses
Total shareholders' equity
At January 1, 2025
4,036 
384,875 
(981)
(246,293)
141,636 
Net result
— 
— 
— 
(49,002)
(49,002)
Remeasurement of net pension liabilities
— 
— 
— 
(301)
(301)
Exchange differences on translating foreign operations
— 
— 
— 
9 
9 
Total comprehensive income
— 
— 
— 
(49,294)
(49,294)
Share-based compensation costs (1)
— 
3,446 
— 
— 
3,446 
Issuance of new shares under LTI plans
1 
— 
— 
— 
1 
Exercise of LTI plans
— 
(112)
173 
— 
62 
Treasury shares withheld to cover social security and tax
— 
— 
(322)
— 
(322)
At September 30, 2025
4,037 
388,209 
(1,129)
(295,588)
95,529 
At January 1, 2026
4,037 
389,179 
(1,129)
(311,753)
80,334 
Net result
— 
— 
— 
(38,410)
(38,410)
Remeasurement of net pension liabilities
— 
— 
— 
6,078 
6,078 
Exchange differences on translating foreign operations
— 
— 
— 
13 
13 
Total comprehensive income
— 
— 
— 
(32,319)
(32,319)
Share-based compensation costs (1)
— 
2,784 
— 
— 
2,784 
Other equity-settled transactions— 154 15 — 169 
Exercise of LTI plans
— 
(180)
280 
— 
100 
Treasury shares withheld to cover social security and tax
— 
— 
(406)
— 
(406)
At September 30, 2026
4,037 
391,937 
(1,240)
(344,072)
50,662 
(1) See note 5.4
See accompanying notes, which form an integral part of these unaudited condensed consolidated interim financial statements.


Explanatory notes to the condensed consolidated interim financial statements

1.    General Information
Molecular Partners AG ("Company") and its subsidiary (collectively "Molecular Partners" or "Group") is a clinical-stage biopharmaceutical company pioneering designed ankyrin repeat proteins (DARPin) candidates to treat serious diseases, with a current focus on oncology and virology. The Company was founded on November 22, 2004, and is domiciled at Wagistrasse 14, 8952 Schlieren, Canton of Zurich, Switzerland. It is subject to the provisions of the articles of association and to article 620 et seq. of the Swiss Code of Obligations, which describe the legal requirements for limited companies (“Aktiengesellschaften”).
Molecular Partners Inc. is a wholly owned subsidiary of Molecular Partners AG. Molecular Partners Inc. was incorporated in the United States in the State of Delaware on October 8, 2018. Molecular Partners Inc. is based in Cambridge, Massachusetts.
The unaudited condensed consolidated interim financial statements for the three and nine months ended September 30, 2026, were approved for issuance by the Audit and Finance Committee on October 26, 2026.
The Company’s shares are listed on the SIX Swiss Exchange (Ticker: MOLN) since November 5, 2014, and on the Nasdaq Global Select Market (Ticker: MOLN) since June 16, 2021.

2.    Basis of Preparation
These unaudited condensed consolidated interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting and should be read in conjunction with the Group's last annual consolidated financial statements as at and for the year ended December 31, 2025. They do not include all the information required for a complete set of consolidated financial statements prepared in accordance with IFRS® Accounting Standards ("IFRS") as issued by the IASB. However, selected explanatory notes are included to explain events and transactions that are significant to gain an understanding of the changes in the Group's financial position and performance since the last annual consolidated financial statements as at and for the year ended December 31, 2025.
The Board of Directors and management have assessed the Group's ability to continue as a going concern for a period of at least twelve months from the date these financial statements are authorized for issue. That assessment concluded that the going concern basis of preparation remains appropriate; however, material uncertainties exist on the current ability to raise funds and on the level of cash and cash equivalents that may cast significant doubt on the Group's ability to continue as a going concern, as described below.
Conditions and events giving rise to material uncertainty
At September 30, 2026, the Group had cash and cash equivalents and short-term financial assets of TCHF57,493. Based on the approved operating plan, existing cash resources are expected to fund operations into Q4 2027. The Company has been unable to obtain additional funding since the last issuance of shares in October 2024. As the Company historically has been dependent on raising funding through the capital markets and to a lesser extent on revenue or cost sharing arrangements, the current situation gives rise to the material uncertainty.
Management's plans and mitigating actions
Management, with oversight from the Board of Directors, has developed and is executing the following plans to address the identified conditions:


•A deepened focus on radiopharmaceuticals and streamlining of capabilities and resources resulting in a pipeline prioritization and operating cost reductions. As a result of this pipeline prioritization, the Company expects there to be no or immaterial impairment exposure. In regard to the operating cost reductions, the Company has informed on October 29, 2026, the Amt für Wirtschaft of Kanton Zürich (Office for Economic Affairs) of its intention to reduce its current workforce by no more than 55 positions, representing a potential of ~44% of all positions. Molecular Partners foresees the full implementation of these changes enacted by Q2 2027 and the reduction of costs to become fully effective early in H2 2027. See note 5.11 for further information.
•Capital raise / equity financing — ongoing efforts to secure additional funding, either through a direct issuance of shares or alternative structures.
The accounting policies set forth in the notes to those annual consolidated financial statements have been consistently applied to all periods presented, except as per below.
The condensed consolidated interim financial statements are presented in thousands of Swiss Francs (TCHF), unless stated otherwise.
The business is not subject to any seasonality. Revenues largely depend on the underlying collaboration agreements and the achievement of agreed milestones, while expenses are largely affected by the phase of the respective projects, particularly with regard to external research and development expenditures.
Due to rounding, the numbers presented in the financial statements might not precisely equal the accompanying notes.
3.    New or Revised IFRS Standards and Interpretations
A number of new or amended standards became applicable for annual periods beginning on or after January 1, 2026. These standards were assessed to not have any significant impact on the Group’s accounting policies and did not require any retrospective adjustments.
A preliminary assessment on the impact of the implementation of IFRS 18 has been performed; based on this assessment, the Company expects there to be no significant impact on the Company's overall financial statements. Based on the initial assessment the Company also expects there to be no Management defined Performance Measures or MPM’s to be reported on. IFRS 18 will not be early adopted. Possible impacts from other new or revised standards have not yet been assessed but are anticipated to be immaterial.
4.    Accounting estimates and judgments
The condensed consolidated interim financial statements have been prepared under the historical cost convention. In preparing these condensed consolidated interim financial statements, management made judgments, estimates and assumptions that not only assess the determination on operating as a going concern, based on the development of our cash balance, but also affect the application of accounting policies and the reported amounts of assets and liabilities, income and expenses. Actual results may differ from these estimates.
5.    Other explanatory notes
5.1    Other group-wide disclosures
On January 5, 2024, the Group announced it entered into a co-development agreement with Orano Med to co-develop 212Pb-based Radio Darpin Therapies (RDT). Under the terms of the co-development agreement, Molecular Partners previously disclosed RDT target DLL3 (delta-like ligand 3) is included in


the collaboration with Orano Med. Both companies agree to share the cost of preclinical and clinical development with additional commitments to supply their respective materials.
The cost sharing in the first nine months of 2026 resulted in a reimbursement of expenses by Orano Med of TCHF710 (First nine months of 2025: TCHF2,030) and for the three months ended September 30, 2026: TCHF285 (Three months ended September 30, 2025: TCHF633) reported under research and development expenses.

5.2    Share capital
As of September 30, 2026, the issued share capital of the Company amounted to CHF 4,037,464 divided into 40,374,641 fully paid registered shares, inclusive of 2,039,227 treasury shares (December 31, 2025: CHF 4,037,464 divided into 40,374,641 shares, of which 2,962,973 were treasury shares).
In CHF thousandsNumber of Treasury sharesAverage price in CHFTotal TCHF value
As of January 1, 2026
2,962,973 
0.38 
1,129 
Shares vested under the PSU program
(881,169)
0.28 
(247)
Shares withheld to cover social security and tax liabilities
105,614 
3.08 
326 
Shares vested under the RSU program
(120,144)
0.28 
(34)
Shares withheld to cover social security and tax liabilities
24,890 
3.23 
80 
Other equity-settled transactions
(52,937)
0.28 
(15)
Shares as of September 30, 2026
2,039,227 
0.61 
1,240 

Treasury shares are measured at a FIFO principle.
The 130,504 shares were withheld from vested awards to cover employees’ and Board of Directors income tax and social security contributions.
5.3    Dividends
The Group has paid no dividends since its inception and does not anticipate paying dividends in the foreseeable future.

5.4    Share-based compensation
As of September 30, 2026, a total of 3,253,411 PSUs and 586,723 Restricted Share Units ("RSUs") were outstanding (as of December 31, 2025, a total of 2,918,458 PSUs and 504,543 RSUs were outstanding). The changes in the number of share-based awards (PSUs and RSUs) outstanding during the nine month period ended September 30, 2026, is as follows:


PSU/ RSU movements3
PSU / RSU (numbers)
Balance outstanding at January 1, 2026
3,423,001 
Granted
1,965,301 
(Performance adjustment)1
(396,151)
(Forfeited)2
(150,704)
(Expired)
— 
(Exercised grants), vested PSU / RSU
(1,001,313)
Balance outstanding at September 30, 2026
3,840,134 
1Performance adjustments indicate additional grants or forfeitures due to non-market performance conditions (under) over-achieved
2Forfeited due to service conditions not fulfilled
3 All outstanding PSU / RSU have an exercise price of CHF 0.10.

The share-based compensation costs recognized during the nine months ended September 30, 2026, amounted to TCHF 2,784 (TCHF 3,446 for the nine months ended September 30, 2025). For the three months ended September 30, 2026, the share-based compensation costs amounted to TCHF 941 (TCHF 1,076 for the three months ended September 30, 2025).
5.5    Financial income and expense

Financial income for nine months
in CHF thousands, for the nine months ended September 30
2026
2025
Interest income on financial assets held at amortized cost
230 
1,288 
Net foreign exchange gain
483 
— 
Total
713 
1,288 
Financial expense for nine months
in CHF thousands, for the nine months ended September 3020262025
Net foreign exchange loss
— (4,767)
Interest expense on leases
(18)(12)
Other financial expenses
(12)(11)
Total
(30)(4,790)

Financial income for three months
in CHF thousands, for the three months ended September 3020262025
Interest income on financial assets held at amortized cost
16 366 
Net foreign exchange gain
346 — 
Total
362 366 

Financial expense for three months



in CHF thousands, for the three months ended September 3020262025
Net foreign exchange loss
— (151)
Interest expense on leases
(5)(3)
Other financial expenses
(4)(4)
Total
(9)(158)

Exchange results primarily represent unrealized foreign exchange results on the cash and short-term time deposit balances held in USD.



5.6    Income taxes
The Group has in recent years reported operating losses, with the exception of the year ended December 31, 2022, that resulted in a tax loss carry-forward in Switzerland of TCHF 252,980 as of December 31, 2025. No deferred tax assets have been recognized for these tax loss carry forwards, because it is not probable that such loss carry forwards can be utilized in the foreseeable future. In addition, no deferred tax positions were recognized on other deductible temporary differences (e.g., pension liabilities under IAS 19) due to the significant tax loss carry forwards.
5.7 Earnings per share
for the nine months ended September 30
2026
2025
Weighted average number of shares used in computing basic and diluted earnings per share38,047,613 37,223,971 

for the three months ended September 30
2026
2025
Weighted average number of shares used in computing basic and diluted earnings per share38,326,000 37,399,154 
5.8    Other Comprehensive result
In order to recognize remeasurements of the net defined benefit obligation in the period in which they arise, the Group utilizes its independent actuaries to update the calculation of the defined benefit obligation and plan assets at each reporting date. The primary components of the remeasurement as of and for the nine month period ended September 30, 2026, relate to an increase in the value of the assets held under the defined benefit plan and changes to demographic assumptions.
5.9    Related parties
The Group did not enter into any related party transactions in the interim periods presented.
5.10    Restructuring expense
For the nine months ended September 30, 2026 no restructuring expense was recognized. For the nine months ended September 30, 2025, the Group recognized TCHF 2,733 as expenses related to the restructuring initiated June 10, 2025. The restructuring charges primarily consisted of personnel related cost.
5.11    Events after the balance sheet date
On October 29, 2026 the Company has informed the Amt für Wirtschaft of Kanton Zürich (Office for Economic Affairs) of its intention, as part of a company restructuring, to reduce its current workforce by no more than 55 positions, representing a potential of ~44% of all positions. In accordance with Swiss employment law, a consultation process with employees has been initiated. Upon completion of the consultation process, the Company will offer affected employees support. Molecular Partners foresees the full implementation of these changes enacted by Q2 2027 and the reduction of costs to become fully effective early in H2 2027. The financial impact from the restructuring is not estimable at this time, as the Company is still assessing the specifics of affected employees.


Other than the workforce reduction described above, no other events occurred between the balance sheet date and the date on which these condensed consolidated interim financial statements were approved for issuance by the Board of Directors that would require adjustment to these condensed consolidated interim financial statements or disclosure under this section.





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Molecular Partners AG
(Registrant)
Date: October 29, 2026
/s/ PATRICK AMSTUTZ
Name:
Patrick Amstutz
Title:
Chief Executive Officer